AUSTIN, Texas, Jan. 4, 2017 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that it has received FDA clearance for the ARIES® Group B Streptococcus (GBS) Assay for antepartum detection of GBS colonization in pregnant women. This is the third assay the FDA has cleared for use on the Luminex ARIES® Systems. The company has also... Read more
AUSTIN, Texas, Jan. 4, 2017 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that it has received FDA clearance for the ARIES® Group B Streptococcus (GBS) Assay for antepartum detection of GBS colonization in pregnant women. This is the third assay the FDA has cleared for use on the Luminex ARIES® Systems. The company has also... Read more
AUSTIN, Texas, Dec. 5, 2016 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that the company was awarded the prestigious R&D 100 Award for its ARIES® Systems at the 54th Annual R&D 100 Awards ceremony in November. The R&D 100 Awards, presented by R&D Magazine, is an international competition that honors the 100 best technologies of... Read more
AUSTIN, Texas, Nov. 7, 2016 /PRNewswire/ — Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the 28th Annual Piper Jaffray Healthcare Conference to be held at the Lotte New York Palace November 29 – 30, 2016, in New York, NY. The investor presentation will begin at 7:30 a.m. Eastern time on Tuesday, November... Read more
AUSTIN, Texas, Oct. 31, 2016 /PRNewswire/ — Luminex Corporation (NASDAQ:LMNX) today announced financial results for the third quarter ended September 30, 2016. Financial and operating highlights include the following: Consolidated third quarter revenue of $71.2 million, an 18% increase compared to the third quarter of 2015. In the third quarter, Nanosphere contributed revenue of $7.4 million,... Read more